Active Biotech AB - Year-end report January - December 2019

Fourth quarter in brief

• The first patient in the Phase 1b/2 study of naptumomab estafenatox in combination with a checkpoint inhibitor in solid tumors was dosed
• Preclinical data on naptumomab estafenatox were presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting
  
  

Other significant events during the January-December period

• Active Biotech's partner NeoTX entered into a clinical collaboration with AstraZeneca to evaluate naptumomab estafenatox in combination with IMFINZI® (durvalumab) in the Phase 1b/2 study
• A patent regarding tasquinimod treatment of acute leukemia was granted in the US
• Active Biotech completed the sale of the property, Forskaren 1, to Estea AB on April 5, 2019. The purchase price amounted to SEK 275 M, equal to its book value and generated an approx. SEK 70 M liquidity injection.
• Michael Shalmi was elected Chairman of the Board and Uli Hacksell as Board member at the Annual General Meeting on May 23, 2019
• An evaluation of the company’s clinical and commercial assets was initiated

Events after the end of the period
      ·A new direction for Active Biotech was approved by the Board (see separate press release from February 5, 2020)
             
             

Financial summary

For further information, please contact:

The report is also available at www.activebiotech.com.

Active Biotech is obligated to make public the information contained in this interim report pursuant to the EU Market Abuse Regulation and the Securities Markets Act. This information was provided to the media, through the agency of the contact person set out above, for publication on February 6, 2020, at 8:30 a.m. CET. 

Attachment

• Q4_2019_Active Biotech_Year End Report